B46.5

Clinical Causes: Inhalation of spores from mucormycetes present in environments like soil, decaying organic matter, or indoor air. Ingestion of contaminated food containing fungal spores. Direct inoculation into tissue through cuts, wounds, or surgeries. Underlying health conditions that weaken the immune system, such as diabetes, cancer, or organ transplantation.

Key Symptoms: Fever and chills Pain and swelling in affected areas Skin discoloration or blackening in infected regions Nasal congestion or sinus pain Headache and facial pain Eye swelling or vision problems if sinus or orbital regions are involved Shortness of breath or cough if lungs are affected Black or necrotic tissue in affected tissues or organs

Diagnosis Path: Diagnosis of mucormycosis typically involves a combination of clinical examination, imaging studies such as CT or MRI scans, laboratory tests including tissue biopsies, and microscopic identification of fungi. Timely diagnosis is vital to prevent the progression of infection and facilitate effective management.

Treatment Protocols: Management of mucormycosis often requires aggressive antifungal therapy, typically with drugs like amphotericin B. Surgical intervention may be necessary to remove necrotic tissue and control the spread of infection. Addressing underlying health issues, such as controlling blood sugar levels in diabetics or reducing immunosuppressive therapy when possible, can also support recovery. Early treatment plays a crucial role in improving outcomes and reducing mortality risk.